Before you sell to, join or invest in Dynocardia, Inc.
MentionFox check on Dynocardia, Inc.: only 2 sources on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/dynocardia-inc-form-d-25000001
Check Dynocardia, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Dynocardia, Inc.?
Based on the records MentionFox holds for this company. No flag is not a clearance.
Dynocardia, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-03-14.
Dynocardia, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on March 14, 2025. The filing reports $1.24M sold. Its industry group is Other Health Care. It names Mohan Thanikachalam (Executive Officer, Director) (SEC Form D/A, March 14, 2025).
Is this your company?
Sell to companies like Dynocardia, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-03-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Dynocardia, Inc.
Free to see. No signup.
More on the people and the money behind Dynocardia, Inc., from the filings we hold.
American Trust Investment Services, Inc. received sales compensation on this raise and on 6 other raises we hold, nearest in date first:
Other Health Care raises by companies based in Massachusetts, filed in March 2025, largest first.
Get an email when Dynocardia, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Dynocardia, Inc. raises, hires or launches. No email unless you switch it on.
Watch Dynocardia, Inc. →Get the full cited report on Dynocardia, Inc.
What the filing shows about Dynocardia, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Dynocardia, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Dynocardia, Inc.'s address as 1188 Center Street Ste 2, Ste 2, Newton Center, MA 02459-1556.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Dynocardia, Inc. →
Amended on 2025-12-12: the amount sold changed from $675,324 to $1,240,638; the number of investors changed from 11 to 20; sales commissions changed from $40,520 to $74,439; finders' fees changed from $13,507 to $24,813. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Dynocardia, Inc. is a registered filer with the SEC (CIK 1776173) and has filed since 2023-04-03. 7 filings are on record, the latest on 2025-12-12.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Dynocardia, Inc.'s Form D of 2025-03-14 names Mohan Thanikachalam as its officers, directors or promoters.
Its new offerings report $2.18M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 863 filings in Other Health Care, totalled by week.
Mohan Thanikachalam is named as Executive Officer and Director on the Form D that Dynocardia, Inc. filed with the SEC on 14 March 2025, the only person that filing names.
1 person named on the filing — 1 holding an executive role.
Named as of the 2025-03-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about Dynocardia, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Dynocardia, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dynocardia, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Dynocardia, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Dynocardia, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Dynocardia, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/dynocardia-inc-form-d-25000001